Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AORT stock price vs HON: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HON's multiple
Needs HON P/E.
Implied fair value · at AORT's multiple
Needs AORT P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ARTIVION, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Honeywell International Inc · implied price per share
Bear
$56.53
Base
$72.18
Bull
$93.05
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
AORT vs ABT
Merck & Co., Inc.
AORT vs MRK
BOSTON SCIENTIFIC CORP
AORT vs BSX
JOHNSON & JOHNSON
AORT vs JNJ
ZIMMER BIOMET HOLDINGS, INC.
AORT vs ZBH
TELEFLEX INC
AORT vs TFX
3M Company
AORT vs MMM
Parker-Hannifin Corp
AORT vs PH
Eaton Corp plc
AORT vs ETN
DANAHER CORP /DE/
AORT vs DHR
EMERSON ELECTRIC CO
AORT vs EMR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AORT can materially expand operating margin and sustain double-digit revenue growth, then you might hold or accumulate selectively because the current price embeds very optimistic execution versus HON and the DCF/HON implied ranges; otherwise, the data favors reducing exposure given the large valuation discount implied by the model.
AORT trades at $27.22 versus an implied P/E value of $7.07, implying 74.0% downside and a clear valuation premium to HON-based and DCF frameworks. The gap is driven by AORT's much higher P/E and EV/EBITDA multiples than HON, despite AORT's smaller scale and lower profitability.
Supporting Metrics
